Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

ASH19 Lymphoma
Biotech

Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows

By Adam Feuerstein

purple lungs ct
Biotech

AstraZeneca study results could change treatment for certain early-stage lung cancer patients

By Adam Feuerstein

coronavirus ct scan
Biotech

A biotech company tries to retrofit a lung drug to prevent Covid-19’s after effects

By Damian Garde

STAT SPOTLIGHT
Biotech

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

By Elizabeth Cooney

Biotech

Moderna executives have cashed out $89M in shares this year, as stock price has soared on vaccine hopes

By Damian Garde

Merck
Biotech

Merck leaps into Covid-19 vaccine race, aiming to test two different candidates this year

By Matthew Herper

IV drip
Biotech

Argenx antibody drug improves symptoms in patients with myasthenia gravis

By Adam Feuerstein

STAT SPOTLIGHT
Biotech

Startup Spotlight: Aiming to speed precision cancer therapies to children

By Elizabeth Cooney

Graph Vs Host Disease
Biotech

Kadmon to seek FDA approval of drug targeting graft-versus-host disease following positive study outcome

By Adam Feuerstein

monkey kidney cells
Biotech

A secret coup and a ‘poison pill’ have frozen shares of a biotech in the race for a Covid-19 vaccine

By Damian Garde

Biotech

Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine

By Helen Branswell

MODERNA - Norwood facility
Adam's Take

Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock

By Adam Feuerstein

glass vials/conveyor belt
Exclusive

Gilead ups its donation of the Covid-19 drug remdesivir for U.S. hospitals

By Eric Boodman

Alexion Pharmaceuticals Inc
Biotech

Alexion becomes latest company to face pressure to sell from activist investor

By Jon Chesto — Boston Globe

Biotech

Pfizer says efficacy of its Duchenne gene therapy outweighs side effects

By Matthew Herper

Remdesivir pricing illo
Biotech

Less than a movie ticket or ‘impossible to overpay’? Experts name their price for remdesivir

By Damian Garde and Ed Silverman

Colon cancer cells
Biotech

Amgen’s KRAS-blocking drug shows small improvement in colon cancer response

By Adam Feuerstein

red/orange lung cancer
Biotech

Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study

By Adam Feuerstein

ASH19 Lymphoma
Biotech

Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show

By Adam Feuerstein

vaginal epithelial cells
Biotech

‘Good’ bacteria could help fight a common vaginal infection, new data show

By Kate Sheridan

FDA
Biotech

FDA refuses application for cell therapy from Bristol and Bluebird, dealing both a major setback

By Matthew Herper

Sickled cell
Biotech

Deluge of genome editing therapies ends research drought for sickle cell disease

By Sharon Begley

MODERNA - Norwood facility
Adam's Take

With high hopes for its Covid-19 vaccine, Moderna stock value requires nearly mythical leap of faith

By Adam Feuerstein

Fatty Liver
Biotech

French drug maker Genfit says NASH drug fails late-stage clinical trial

By Adam Feuerstein

Aviv Regev portrait
Biotech

Prominent Broad Institute scientist leaves to lead R&D at Genentech

By Elizabeth Cooney

Anatomical heart
Biotech

Results indicate MyoKardia drug is a ‘potential game changer’ for heart condition

By Matthew Herper

Something ventured illo
Something Ventured

Dyne Therapeutics and three other startups got venture funding a year ago. Will it be enough to get them through Covid-19?

By Kate Sheridan

Adam's Take

CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed

By Adam Feuerstein

Biotech

Digital event: Combating Covid-19 — Part 3

By Matthew Herper

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy